alexa Bridging The Gaps Of China GCP Regulation Compared To ICHGCP To Effectively Conduct Multinational Clinical Trials (MCTs) | 14202
ISSN: 2329-6631

Journal of Developing Drugs
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Summit on GMP, GCP & Quality Control
November 12-14, 2013 DoubleTree by Hilton Hotel Chicago-North Shore, IL, USA

Libin Zhao, Henry Sun and Zhixin Guo
Accepted Abstracts: J Develop Drugs
DOI: 10.4172/2329-6631.S1.004
Abstract
Currently, with the regulatory harmonization of the US, EU, JP, CN and the related countries/regions internationally, the discovery, development, authorization and marketing of the new drugs is also moving toward the globalization, this trend results in the evolution of clinical strategies that more and more clinical trials could be conducted in multiple countries simultaneously to prevent unnecessarily duplicated studies and make drug development more efficient and cost-effective, therefore, the establishment of the mutual standardization, understanding and implementation of the GCP principle are now extremely concerned and driven by the regulators, sponsors and the investigators worldwide considering the ethnic and race factors with a large of world populations. Chinese GCP regulation was firstly introduced by the Ministry of Health (MOH) in March1998with reference to WHO, ICH 4 ICH and EC guideline, and then the practice was revised again by the new competent authority (SFDA) in 2003 to apply to China?s actual pharmaceutical environment. In the recent 5 years, a large number of the international (ICH, FDA and EU) guidelines are being adopted as well to pace up with the evolution of the international GCP. Chinese GCP includes 13 chapters with the total 70 articles, whose general aspects of the principles and contents are compatible with ICHGCP, however, in details the special situation was considered to better implement China GCP, e.g. clinical regulatory review/approval, qualification of the investigators/clinical sites, IEC/IR Band, etc. Compared to the current clinical development in the USA, EU and some other western countries, the conduct of the clinical trials in China is merging because of the highly accessible subject, comparable expense, increased well-educated staffs, improved regulatory environment and flexible regulations to encourage innovation, China?s clinical data is being more credible, reliable and internationally recognized, the escalated number of the global clinical trials has stated that this regulatory gap is bridging between in China and ICH countries. T89, one of the pioneer botanical products exploring the FDA approval, also will be employed as the case story to show this evolution.
Biography
Libin Zhao is the Associate Director of Tasly Global Regulatory Affairs Department of Tianjin Tasly Group Co. Ltd, one of the leading pharmaceutical & botanical product enterprises in China. He has more than 15 years of industrial experience and published more than 20 papers in China?s scientific journals/publications.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version